BioKuris
The computed 12-month bankruptcy probability of BioKuris is 0.8% (low). The 2025 annual accounts show equity of €1.05M and a net result of €-1.68M. Equity is shrinking by ~44.8% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2026. Its solvency ranks better than 30% of 81 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €1.05M |
| Net result | €-1.68M |
| Staff (FTE) | 1 |
| Better than sector | 30% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 18.0% | 49.8% | |
| Net result | €-1.68M | €17k | |
| Equity | €1.05M | €102k | |
| Gross operating margin | €-512k | €49k | |
| Total assets | €5.85M | €250k |
| Fiscal year | 2025 |
|---|---|
| Deposit | volledig |
| Revenue | €700k |
| EBITDA | €-571k |
| Net profit | €-1.68M |
| Cash flow | €-608k |
| Staff costs | €59k |
| Income taxes | - |
| Dividends | - |
| Total assets | €5.85M |
| Equity | €1.05M |
| Debt | €4.79M |
| of which ≤ 1y | €1.78M |
| of which > 1y | €3.01M |
| Working capital | €-877k |
| Employees (FTE) | 1.0 |
| 2025 | |
|---|---|
| Current ratio | 0.51 |
| Quick ratio | 0.51 |
| Working capital ratio | -15.0% |
| Solvency | 18.0% |
| Debt / equity | 4.56 |
| Long-term debt ratio | 2.87 |
| Interest coverage | -15.41 |
| Gross margin | -225.5% |
| Net margin | -239.6% |
| ROA | -28.7% |
| ROE | -159.7% |
| EBITDA margin | -81.5% |
| Days sales outstanding | 57d |
| Days payable outstanding | 114d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €5.85M |
| Fixed assets | 21/28 | €4.94M |
| Formation expenses | 20 | €957 |
| Intangible fixed assets | 21 | €4.94M |
| Current assets | 29/58 | €904k |
| Amounts receivable within one year | 40/41 | €681k |
| Cash & bank | 54/58 | €223k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €5.85M |
| Equity | 10/15 | €1.05M |
| Contributions / capital | 10/11 | €1.52M |
| Accumulated profits (losses) | 14 | €-2.63M |
| Amounts payable | 17/49 | €4.79M |
| Amounts payable after one year | 17 | €3.01M |
| Amounts payable within one year | 42/48 | €1.78M |
| Trade debts payable within one year | 44 | €712k |
| Income statement | ||
| Turnover | 70 | €700k |
| Gross operating margin | 9900 | €-512k |
| Operating result | 9901 | €-1.64M |
| Financial income | 75 | €63 |
| Financial charges | 65 | €37k |
| Result before taxes | 9903 | €-1.68M |
| Net result for the period | 9904 | €-1.68M |
| Result to be appropriated | 9905 | €-1.68M |
-
KITOZYME SALegal entityDirector· perm. rep.: Marie HobéState Gazette act 24157050 (31-10-2024)Current31-10-2024 → present
2 events
- 31-10-2024 Appointed· Director
- 31-10-2024 Mandate renewed· Director
-
Sparaxis SALegal entityDirector· perm. rep.: Géry LefèbvreState Gazette act 26006450 (14-01-2026)Current11-04-2023 → present
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| EY Réviseurs d'Entreprises SRLCurrent Statutory auditor · represented by Marie-Laure Moreau |
- | 31-10-2024 → present |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 08-06-2021 |
| Status | Active |
| Postal code | 4040 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62312A0796/00G000 | Wallonia | 969 m² | - | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
14-01-2026 Géry Lefèbvre appointed as director
- Géry Lefèbvre, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "G\u00E9ry Lef\u00E8bvre",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "SPARAXIS SA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-04-11",
"evidence_quote": "Afin de r\u00E9gulariser r\u00E9troactivement une erreur administrative, il est propos\u00E9 \u00E0 l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire de nommer comme Administrateur: -G\u00E9ry Lef\u00E8bvre, repr\u00E9sentant SPARAXIS SA"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.454.379",
"name_full": "BIOKURIS",
"legal_form": "SA"
}
}26-06-2025 Capital decrease of €5,000,000 to €2,898,496.36
- €7.898.496,36 → €2.898.496,36
Technical details
{
"events": [
{
"kind": "capital_decrease",
"amount": 5000000,
"currency": "EUR",
"after_eur": 2898496.36,
"delta_eur": -5000000.0,
"before_eur": 7898496.36,
"amount_type": "kapitaal_effectief",
"effective_date": "2025-05-26",
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de r\u00E9duire le capital de cinq millions d\u2019euros (5.000.000.-\u20AC) pour le ramener de sept millions huit cent nonante-huit mille quatre cent nonante-six euros trente-six cents (7.898.496,36.-\u20AC) \u00E0 deux millions huit cent nonante-huit mille quatre cent nonante-six euros trente-six cents (2.898.496,36.-\u20AC)",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.454.379",
"name_full": "BIOKURIS",
"legal_form": "SA"
}
}31-10-2024 2 directors appointed, 1 resigning, 1 reappointed
- Marie Hobé, Bestuurder
- Marie-Laure Moreau, Commissaris
- KITOZYME SA, Bestuurder
- Marie Hobé, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "KITOZYME SA",
"address": null,
"birth_date": null
},
"effective_date": "2022-12-31",
"evidence_quote": "Fran\u00E7ois Luthers remet sa d\u00E9mission en tant qu\u0027administrateur de BiOkuris (repr\u00E9sentant KitoZyme); d\u00E9mission effective le 31/12/2022."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Marie Hob\u00E9",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KITOZYME SA",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "Il est propos\u00E9 \u00E0 l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Ordinaire la nomination d\u0027un nouveau mandat: Marie Hob\u00E9, repr\u00E9sentant KITOZYME SA pour une dur\u00E9e de 1 an... L\u0027Assembl\u00E9e G\u00E9n\u00E9rale Ordinaire approuve la nomination telle que propos\u00E9e \u00E0 l\u0027unanimit\u00E9 des voix."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Marie Hob\u00E9",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KITOZYME SA",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "Il est propos\u00E9 \u00E0 l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Ordinaire le renouvellement du mandat comme suit: -Marie Hob\u00E9, repr\u00E9sentant KITOZYME SA, pour une dur\u00E9e de 2 ans... L\u0027Assembl\u00E9e G\u00E9n\u00E9rale Ordinaire approuve la nomination telle que propos\u00E9e \u00E0 l\u0027unanimit\u00E9 des voix."
},
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Marie-Laure Moreau",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "Le commissaire aux comptes EY R\u00E9viseurs d\u0027Entreprises SRL repr\u00E9sent\u00E9 par Marie-Laure Moreau est nomm\u00E9 pour une p\u00E9riode de 3 ans..."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.454.379",
"name_full": "BIOKURIS",
"legal_form": "SA"
}
}03-01-2022 Capital increase of €5,336,996.36 to €5,398,496.36
- €61.500 → €5.398.496,36
- 3 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 5336996.36,
"currency": "EUR",
"after_eur": 5398496.36,
"delta_eur": 5336996.36,
"before_eur": 61500.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2021-12-23",
"evidence_quote": "Augmentation de capital \u00E0 concurrence de cinq millions trois cent trente-six mille neuf cent nonante-six euros trente-six cents (5.336.996,36 \u20AC) pour le porter de soixante-et-un mille cinq cents euros (61.500,00 \u20AC) \u00E0 cinq millions trois cent nonante-huit mille quatre cent nonante-six euros trente-six cents (5.398.496,36 \u20AC)",
"contribution_type": "in_kind"
},
{
"kind": "capital_increase",
"amount": 1250000.0,
"currency": "EUR",
"after_eur": 6648496.36,
"delta_eur": 1250000.0,
"before_eur": 5398496.36,
"amount_type": "kapitaal_effectief",
"effective_date": "2021-12-23",
"evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital \u00E0 concurrence de un million deux cent cinquante mille euros (1.250.000,00\u20AC) pour le porter de cinq millions trois cent nonante-huit mille quatre cent nonante-six euros trente-six cents (5.398.496,36 \u20AC) \u00E0 six millions six cent quarante-huit mille quatre cent nonante-six euros trente-six cents (6.648.496,36 \u20AC)",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 1250000.0,
"currency": "EUR",
"after_eur": 7898496.36,
"delta_eur": 1250000.0,
"before_eur": 6648496.36,
"amount_type": "kapitaal_effectief",
"effective_date": "2021-12-23",
"evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital \u00E0 concurrence de un million deux cent cinquante mille euros (1.250.000,00\u20AC) pour le porter de six millions six cent quarante-huit mille quatre cent nonante-six euros trente-six cents (6.648.496,36 \u20AC) \u00E0 sept millions huit cent nonante-huit mille quatre cent nonante-six euros trente-six cents (7.898.496,36 \u20AC)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.454.379",
"name_full": "BIOKURIS",
"legal_form": "SA"
}
}10-06-2021 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "Rue de Milmort 680, 4040 Herstal",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": "0473.676.932",
"name": "KITOZYME"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "sans d\u00E9signation de valeur nominale",
"partner_role": null,
"holder_org_kbo": "0473.676.932",
"holder_org_name": "KITOZYME",
"contribution_type": "cash",
"amount_paid_in_eur": 36900,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 369,
"amount_subscribed_eur": 36900,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": "0465.880.805",
"name": "INNODE"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "sans d\u00E9signation de valeur nominale",
"partner_role": null,
"holder_org_kbo": "0465.880.805",
"holder_org_name": "INNODE",
"contribution_type": "cash",
"amount_paid_in_eur": 12300,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 123,
"amount_subscribed_eur": 12300,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "CEMAVI"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "sans d\u00E9signation de valeur nominale",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "CEMAVI",
"contribution_type": "cash",
"amount_paid_in_eur": 12300,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 123,
"amount_subscribed_eur": 12300,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 61500,
"subject_company": {
"kbo": "0769.454.379",
"name_full": "BioKuris",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2021-06-07",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | BioKuris |